Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Dermatitis » Eczema
Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Skin Diseases, Eczematous » Eczema
Description
A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed). MeSH
Hierarchy View
Subtype Terms (1)
Eczema, Dyshidrotic
1 experimental drug
Phase 4 Indicated Drugs (12)
Phase 3 Indicated Drugs (30)
Phase 2 Indicated Drugs (38)
Phase 1 Indicated Drugs (7)
Other Experimental Indicated Drugs (18)
Organization Involved with Phase 4 Indications (64)
1st Allergy & Clinical Research Center
Atopic Dermatitis Research Network
Beijing Bionovo Medicine Development Co., Ltd.
Hoosier Cancer Research Network
Icahn School of Medicine at Mount Sinai
National Institute for Health Research, United Kingdom
National Institute of Allergy and Infectious Diseases (NIAID)
Oregon Health and Science University
Smerud Medical Research Denmark
Society for Pediatric Dermatology
St. Luke's-Roosevelt Hospital Center
Technical University of Dresden
Organization Involved with Phase 3 Indications (64)
Gottfried Wilhelm Leibniz Universität Hannover
Korea Research Institute of Bioscience & Biotechnology
National Hepatology & Tropical Medicine Research Institute
Novum Pharmaceutical Research Services
Organization Involved with Phase 2 Indications (166)
AVVAA World Healthcare Products, Inc.
Badalona Hospital Germans Trias i Pujol
BioMimetix Pharmaceutical, Inc.
Centre de Recherche Dernatologique du Quebec
Forest Hills Dermatology Group
Hemay Pharmaceutical PTY. LTD.
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Hospital Universitario Virgen Macarena
Huazhong University of Science and Technology
Instituto Dermatologico y Cirugia de Piel
Maccabi Healthcare Services, Israel
Mayanei Hayeshua Medical Center
National Polytechnic Institute, Mexico
National University of Singapore
Provectus Biopharmaceuticals, Inc.
Reistone Biopharma Company Limited
Shanghai University of Traditional Chinese Medicine
Shulov Innovate for Science Ltd.
Sterna Biologicals GmbH & Co. KG
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Technical University of Munich
Texas Dermatology and Laser Specialists
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
Universitaetsklinikum Schleswig-Holstein
University of Colorado, Denver
University of Medicine and Dentistry of New Jersey
Organization Involved with Phase 1 Indications (16)
Organization Involved with Other Experimental Indications (42)
Clinica Pediatrica Ospedale dei Bambini Vittore Buzzi
Cosmetique Active International
German Federal Ministry of Education and Research
Hospital General Dr. Manuel Gea Gonzalez
Institut National de la Santé Et de la Recherche Médicale, France
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.